Topic:

Clinical Trials

Latest Headlines

Latest Headlines

PaxVax' oral cholera vaccine succeeds in PhIII challenges

PaxVax' single-dose oral cholera vaccine candidate, PXVX0200, posted positive results in a pair of challenge studies, the company announced earlier this week.

Agenus brain cancer vaccine boosts survival in PhII trial

Patients with a lethal form of brain cancer lived nearly twice as long as expected after receiving Agenus' ($AGEN) Prophage vaccine in a Phase II study, according to the company.

UPDATED: Agenus' genital herpes vax cuts viral load 75% in PhII

After hitting its primary endpoint in a Phase II study last fall, Agenus was already leading a Sanofi-NIH collaboration in efforts to develop the first genital herpes vaccine. Now, it's built on that lead with new Phase II results for its therapeutic candidate, HerpV, which achieved statistical significance in reducing viral load.

Parexel rolls out new eClinical tech to speed up study start-up

Parexel International has reformatted its clinical trial management software, streamlining its services with an update the company believes can help its clients start studies faster.

Inovio shares dive on cervical cancer vax speculation

Shares of Inovio Pharmaceuticals took a hit Tuesday on rumors that CEO Joseph Kim was "walking back expectations" for a Phase II study of DNA vaccine candidate VGX-3100 in women with cervical precancerous lesions.

Myriad/Crescendo's rheumatoid arthritis test shows viability in new trial

Myriad Genetics paid $270 million for Crescendo Bioscience in February, and now a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity.

Pfizer prepares to file for approval with positive PhII MenB data

Last March, Pfizer announced it would file for approval for its meningitis B candidate. Now, it has positive results from a pair of midstage trials for the jab that will keep it on track for expedited approval--and a showdown with Novartis' Bexsero.

Dynavax initiates PhIII study it hopes will quell FDA's safety concerns

FDA and EMA requests for more data on hepatitis B candidate Heplisav have set Dynavax Technologies back time and again. Now, Dynavax is embarking on a new trial it hopes will address some of those safety concerns.

Merck KGaA lung cancer vaccine gets a second shot with start of PhIII trial

Merck KGaA has breathed some life back into its lung cancer vaccine, which many wrote off after it tanked in a Phase III trial in late 2012. After vowing to make a renewed effort to find some value in the jab last September, this week the company announced the start of a new Phase III study.

Clinipace signs up to get a brain-stimulating device on the U.S. market

Global CRO Clinipace has agreed to manage clinical trials for Nexstim as the Finnish devicemaker works toward FDA approval for its neurostimulation therapy.